Sandoz Group AG

Sandoz Group AG is a leading Swiss-based pharmaceutical company specializing in the production of generic medicines and biosimilars. With a history tracing back to 1886, the company has evolved into one of the world’s foremost providers in its sector, serving hospitals, pharmacies, and healthcare providers across more than 40 countries. Sandoz’s primary function is to develop, manufacture, and distribute high-quality, affordable pharmaceuticals that enhance patient access to essential therapies, accounting for a significant share of global medicine supplies. The company operates across two main business segments: generics, which are off-patent small-molecule drugs, and biosimilars, which are highly similar versions of biological medicines. This dual focus allows Sandoz to serve a wide range of therapeutic areas and contribute critically to healthcare cost containment. Following its 2023 spin-off from Novartis, Sandoz has established itself as an independent entity headquartered in Basel, Switzerland, with major operations extending throughout Europe and North America. Its strategic commitment to pioneering access for patients drives innovations, making Sandoz a key player in improving healthcare outcomes worldwide.